Benzodiazepine overdose causes CNS depression through GABA-A receptor agonism, ranging from drowsiness to coma, with the primary life-threatening mechanism being respiratory compromise from loss of protective airway reflexes. Isolated benzodiazepine poisoning rarely causes life-threatening hypoventilation or hemodynamic instability — most fatalities involve coingestants (opioids, alcohol, other CNS depressants). [1-2] Management is primarily supportive care with airway management; flumazenil is reserved for select low-risk cases. [1-2]
1. History
- What was ingested? Specific benzodiazepine (short-acting: alprazolam, midazolam vs. long-acting: diazepam, clonazepam), amount, formulation (immediate vs. extended release)
- Time of ingestion — critical for GI decontamination decisions and predicting peak effects
- Intentional vs. accidental — suicidal intent, recreational use, pediatric exploratory ingestion, iatrogenic (procedural sedation)
- Coingestants — opioids, alcohol, TCAs, other sedative-hypnotics, anticonvulsants. This is the single most important historical question, as mixed overdose dramatically changes morbidity/mortality [1-2]
- Chronic benzodiazepine use — tolerance and dependence status (critical for flumazenil decision-making) [1][3]
- Symptom progression — drowsiness → confusion → slurred speech → ataxia → unresponsiveness
- Important negatives: Chest pain, seizure activity, vomiting, head trauma
2. Alarm Features
- Respiratory depression (RR <12, SpO₂ <90%, apnea) — the primary mechanism of death [1-2]
- Hemodynamic instability — markedly abnormal BP or HR strongly suggests coingestant involvement [4-5]
- Coma / GCS ≤8 — loss of airway protective reflexes, aspiration risk
- Seizures — not expected with isolated benzodiazepine OD; suggests coingestant (TCA, tramadol) or withdrawal
- Paradoxical agitation — rare but can occur (agitation, violence, impulsivity) [4][6]
- Hypothermia — prolonged immobilization
- Markedly abnormal vital signs in any direction raise concern for polypharmacy overdose [4-5]
3. Medications
Antidote — Flumazenil (competitive GABA-A antagonist): [3]
- Dosing for overdose: 0.2 mg IV over 30 seconds → if no response after 30 sec, give 0.3 mg → then 0.5 mg doses at 1-minute intervals up to 3 mg total [3]
- Duration of action: 45–90 minutes; resedation is common with long-acting benzodiazepines [3]
- Maximum: 3 mg in any one hour; repeat doses at ≥20-minute intervals [3]
Flumazenil contraindications / high-risk situations: [1-3]
- Chronic benzodiazepine dependence (risk of refractory withdrawal seizures)
- Suspected TCA or other proconvulsant coingestant
- Seizure disorder treated with benzodiazepines
- Undifferentiated coma with unknown history
- Signs of cyclic antidepressant toxicity (wide QRS, mydriasis, twitching) [3]
Safe flumazenil use is limited to: [1-2]
- Iatrogenic oversedation during procedural sedation
- Pediatric exploratory ingestions
- Known isolated benzodiazepine ingestion with no chronic use
Naloxone — should be administered empirically if opioid coingestant is suspected; opioid poisoning is more common and causes more significant respiratory depression, and naloxone has a better safety profile than flumazenil [1-2]
4. Diet
- NPO if altered mental status or risk of aspiration
- No specific dietary triggers or long-term dietary management relevant to acute overdose
- Hydration with IV fluids as part of supportive care [4]
5. Review of Systems
- Neuro: Level of consciousness, confusion, dysarthria, ataxia, seizure activity
- Respiratory: Dyspnea, apnea, snoring/stridor (airway obstruction)
- GI: Nausea, vomiting (aspiration risk), last oral intake
- Psych: Suicidal ideation, self-harm intent, psychiatric history
- MSK: Prolonged immobilization → rhabdomyolysis, compartment syndrome
- Skin: Track marks (IV drug use), transdermal patches, cyanosis [7]
6. Collateral History and Family History
- EMS report — scene findings, pill bottles, drug paraphernalia, suicide note
- Family/friends — medication access, recent behavioral changes, substance use history, prior overdose attempts
- Pharmacy records — prescribed benzodiazepines, opioids, TCAs, anticonvulsants
- Psychiatric history — prior suicide attempts, current mental health treatment
- Family history of substance use disorder or psychiatric illness may inform disposition planning
7. Risk Factors
- Polypharmacy — concurrent opioid prescriptions (the leading risk factor for fatal BZD overdose) [1-2]
- Substance use disorder — alcohol, opioids, illicit drug use
- Elderly patients — increased sensitivity, prolonged metabolism, fall risk
- Hepatic impairment — prolonged benzodiazepine metabolism (especially diazepam, chlordiazepoxide)
- Chronic benzodiazepine use — tolerance leading to dose escalation
- Psychiatric comorbidities — depression, anxiety disorders, prior suicide attempts
- Respiratory comorbidities — COPD, OSA increase vulnerability to respiratory depression
8. Differential Diagnosis
- Opioid overdose — miosis, more profound respiratory depression, responds to naloxone
- Alcohol intoxication — odor of alcohol, elevated BAL; frequently coingested
- TCA overdose — wide QRS, anticholinergic signs (mydriasis, dry mucosa, tachycardia, urinary retention)
- GHB/barbiturate overdose — similar sedation profile; barbiturates cause more cardiovascular depression
- Hypoglycemia — check point-of-care glucose immediately
- Hepatic encephalopathy — asterixis, elevated ammonia
- Structural CNS pathology — stroke, intracranial hemorrhage (focal deficits, asymmetric exam)
- Postictal state — tongue laceration, incontinence, witnessed seizure
- Carbon monoxide poisoning — headache, cherry-red skin, environmental exposure
- Hypothyroidism/myxedema coma — hypothermia, bradycardia, delayed relaxation of reflexes
9. Past Medical History
- Prior overdose attempts or self-harm
- Chronic benzodiazepine prescription (duration, dose — critical for flumazenil risk assessment) [1][3]
- Seizure disorder (flumazenil contraindication) [3]
- Psychiatric diagnoses and current medications (especially TCAs, SSRIs)
- Hepatic or renal disease (affects drug metabolism and clearance)
- Respiratory disease (COPD, OSA)
- Substance use history including alcohol use disorder
10. Physical Exam
- Vitals: Respiratory rate (most critical), SpO₂, BP, HR, temperature. Markedly abnormal vitals suggest coingestant [4-5]
- Neuro: GCS, pupil size and reactivity (benzodiazepines typically cause normal to mildly dilated pupils — miosis suggests opioid, mydriasis suggests anticholinergic), speech, gait if ambulatory [7]
- Airway: Patency, gag reflex, secretions, stridor
- Respiratory: Rate, depth, pattern, breath sounds (aspiration)
- Cardiovascular: Rate, rhythm, perfusion
- Skin: Color (cyanosis), temperature, moisture, track marks, patches [7]
- Musculoskeletal: Tone (expect hypotonia), reflexes (expect diminished) [4-5]
- GI: Bowel sounds (absent in anticholinergic toxidrome)
- Expected findings in isolated BZD OD: Drowsiness, dysarthria, ataxia, hypotonia, diminished reflexes, normal pupils, relatively preserved hemodynamics [4]
11. Lab Studies
- Point-of-care glucose — rule out hypoglycemia immediately
- Serum acetaminophen and salicylate levels — standard in all intentional overdoses to rule out occult coingestant
- Ethanol level
- BMP — electrolytes, renal function, glucose, anion gap
- CBC — baseline
- VBG/ABG — if respiratory depression present (assess for hypercarbia, hypoxemia)
- Urine drug screen — qualitative; note that many newer benzodiazepines (clonazepam, lorazepam, alprazolam) may not be detected on standard immunoassays
- Serum benzodiazepine levels — generally not clinically useful and not routinely recommended; management is guided by clinical presentation
- Hepatic function — if hepatotoxic coingestant suspected
- CK — if prolonged immobilization (rhabdomyolysis risk)
- Lactate — if hemodynamic instability [7]
12. Imaging
- Chest X-ray — if aspiration suspected, intubated, or respiratory distress
- CT head — if altered mental status out of proportion to expected benzodiazepine effect, focal neurologic findings, or history of trauma/fall
- Routine imaging is not necessary for straightforward isolated benzodiazepine overdose with expected clinical trajectory
13. Special Tests
- Glasgow Coma Scale — serial assessments to document and communicate level of impairment [7]
- Capnography (ETCO₂) — continuous monitoring for hypoventilation, especially useful in patients who maintain SpO₂ on supplemental O₂ but are hypoventilating
- Poison Control consultation (1-800-222-1222) — recommended for all significant overdoses [4]
- Toxicology consultation — for complex mixed overdoses, flumazenil decision-making, or refractory cases [8]
14. ECG
- Obtain ECG in all intentional overdoses — primarily to evaluate for coingestant toxicity [7]
- Isolated benzodiazepine OD: ECG is typically normal or shows mild sinus bradycardia
- Critical findings suggesting coingestant:
- Wide QRS (>100 ms) → TCA toxicity (sodium channel blockade) — flumazenil contraindicated [3]
- Prolonged QTc → antipsychotic, methadone, or other QT-prolonging drug
- Bradycardia → beta-blocker, calcium channel blocker, opioid coingestant
- Flumazenil may precipitate dysrhythmias (SVT, ventricular dysrhythmias, asystole) in the presence of dysrhythmogenic coingestants [1-2]
15. Assessment
Severity stratification
- Mild: Drowsiness, confusion, dysarthria, ataxia — maintains airway and adequate ventilation
- Moderate: Significant somnolence, hypotonia, diminished reflexes — requires close monitoring
- Severe: Coma, respiratory depression, loss of airway reflexes — requires airway intervention [4-5]
Key clinical pearl: Isolated benzodiazepine overdose is rarely fatal in adults. If a patient presents with significant hemodynamic instability, profound respiratory depression, or cardiac arrest, always suspect coingestants — particularly opioids, alcohol, or TCAs. [1-2] The clinical course of isolated BZD OD is generally benign with supportive care alone. [8]
16. Treatment Plan
Initial stabilization (ABCs)
- Airway: Positioning, jaw thrust, suctioning. Bag-mask ventilation for apnea/hypoventilation. Endotracheal intubation if unable to maintain airway or ventilation [1]
- Breathing: Supplemental O₂, continuous pulse oximetry and capnography
- Circulation: IV access, IV fluids, cardiac monitoring
GI decontamination
- Activated charcoal (1 g/kg, max 50–100 g) — may be considered if presenting within 1–2 hours of a significant ingestion with intact/protected airway. Not a benzodiazepine-specific recommendation in the 2026 Clinical Toxicology Recommendations Collaborative guidelines, but benzodiazepines are generally well-adsorbed by charcoal [8-10]
- No role for gastric lavage, ipecac, or whole bowel irrigation in isolated BZD overdose
Antidote
- Flumazenil — only in carefully selected low-risk patients (see Medications section above) [1-3]
- Naloxone 0.4–2 mg IV — administer empirically if opioid coingestant suspected [1-2]
Supportive care
- Continuous cardiorespiratory monitoring
- DVT prophylaxis if prolonged immobilization [8]
- Aspiration precautions (lateral decubitus positioning if not intubated)
- Rewarming if hypothermic
- IV fluid resuscitation for hypotension
Benzodiazepines are not significantly removed by dialysis [11]
17. Disposition
Admission / ICU criteria
- Endotracheal intubation or mechanical ventilation
- Persistent respiratory depression or hemodynamic instability
- Significant coingestant requiring monitoring (TCA, opioid, etc.)
- Recurrent sedation after flumazenil (resedation risk) [3]
- Suicidal intent requiring psychiatric evaluation under safe conditions
Observation criteria
- Moderate sedation with stable vitals — observe until clinically sober and ambulatory (typically 4–6 hours for short-acting agents, longer for long-acting)
- Post-flumazenil monitoring for at least 2 hours for resedation [3]
Discharge criteria
- Alert, oriented, ambulatory with stable vitals
- Adequate respiratory function off supplemental O₂
- Able to tolerate oral intake
- Psychiatric clearance if intentional overdose
- Safe disposition plan (reliable adult supervision)
Specialist consultation triggers
- Toxicology — complex mixed overdose, flumazenil decision-making, refractory cases [8]
- Psychiatry — all intentional overdoses before discharge
- Critical care — intubated patients, hemodynamic instability
18. Follow Up / Return Precautions
Follow-up timing
- PCP within 48–72 hours
- Psychiatry follow-up within 1 week if intentional overdose
- Substance use counseling referral if applicable [12-13]
Return precautions — instruct patient/family to return immediately for:
- Recurrent drowsiness or difficulty waking (resedation, especially with long-acting agents)
- Difficulty breathing or noisy breathing
- Confusion or altered behavior
- Vomiting (aspiration risk)
- Seizures
Patient counseling
- Avoid alcohol and other CNS depressants
- Discuss safe medication storage (especially with children in the home)
- If prescribed benzodiazepines chronically, do not abruptly discontinue — risk of withdrawal seizures [12-13]
- Naloxone co-prescription if concurrent opioid use
- Expected recovery: isolated BZD overdose typically resolves within 6–24 hours depending on the agent's half-life
References
1. 2023 American Heart Association Focused Update on the Management of Patients With Cardiac Arrest or Life-Threatening Toxicity Due to Poisoning: An Update to the American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care. — Lavonas EJ, Akpunonu PD, Arens AM, et al. Circulation. 2023.
2. Part 10: Adult and Pediatric Special Circumstances of Resuscitation: 2025 American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care. — Cao D, Arens AM, Chow SL, et al. Circulation. 2025.
3. FDA Drug Label. — Updated date: 2020-01-03. Food and Drug Administration.
4. FDA Drug Label. — Updated date: 2025-07-09. Food and Drug Administration.
5. FDA Drug Label. — Updated date: 2026-01-29. Food and Drug Administration.
6. FDA Drug Label. — Updated date: 2024-04-09. Food and Drug Administration.
7. Acute Medication Poisoning. — Vega IL, Griswold MK, Laskey D. American Family Physician. 2024.
8. Strategies for the Treatment of Acute Benzodiazepine Toxicity in a Clinical Setting: The Role of Antidotes. — Zamani N, Hassanian-Moghaddam H, Zamani N. Expert Opinion on Drug Metabolism & Toxicology. 2022.
9. Recommendations From the Clinical Toxicology Recommendations Collaborative on the Administration of Activated Charcoal in Acute Oral Overdose. — Hoegberg LCG, Gosselin S, Buckley NA, et al. Clinical Toxicology. 2026.
10. Gut Decontamination in the Poisoned Patient. — Gosselin S, Hoegberg LCG, Hoffman RS. British Journal of Clinical Pharmacology. 2025.
11. FDA Drug Label. — Updated date: 2024-04-10. Food and Drug Administration.
12. The Joint Clinical Practice Guideline on Benzodiazepine Tapering: Considerations when Benzodiazepine Risks Outweigh Benefits. — Emily Brunner, Chwen-Yuen A. Chen, Tracy Klein, et al American College of Medical Toxicology (2024). 2024.
13. The Joint Clinical Practice Guideline on Benzodiazepine Tapering: Considerations When Benzodiazepine Risks Outweigh Benefits. — Emily Brunner MD DFASAM, Chwen-Yuen A. Chen MD FACP FASAM, Tracy Klein PhD FNP ARNP FAANP FRE FAAN, et al American Society of Addiction Medicine (2025). 2025.